The contact-lens induced infections market is estimated to reach USD 491.3 million in 2024. It is estimated that revenue will increase at a CAGR of 4.9% between 2024 and 2034. The market is anticipated to reach USD 792.6 million by 2034.
Contact-lens Induced Infections are the microbial infections of part or all of the eye (often cornea and conjunctiva) related to poor use, care or fit with contacts. If left untreated, these infections can cause serious eye issues like keratitis and possibly vision loss.
Its prevalence has been on the rise in recent years attributed mostly to higher number of contact lens users and failure to comply with recommended guidelines for proper care of lenses. The causes also include from poor hygiene to overextended lens wear to contaminants in the contact-lens case. The increased popularity of cosmetic and extended-wear lenses, frequently worn without appropriate medical supervision has also played an anticipating role.
Contact-lens Induced Infections Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 463.1 million |
| Estimated Size, 2024 | USD 491.3 million |
| Projected Size, 2034 | USD 792.6 million |
| Value-based CAGR (2024 to 2034) | 4.9% |
With the current rise in cases of visual impairment and the growing preference for non-invasive, aesthetic solutions in the correction of vision, the global population of contact lens users has been continuing to rise. This indicating to surging demand for contact lenses among young and middle-aged populations due to factors such as myopia, hyperopia, and presbyopia. Ease and cosmetic appeal compared to the traditional eyeglasses are another reason contributing to the popularity of contact lenses across the world.
This has, however, led to increased contact lens-induced infections. Most of these are bacterial keratitis resulting from a failure to clean and replace them on time. Inadequate hygiene, which involves sleeping in them or using dirty solutions, are some of the cause of these infections, which may lead to severe complications if it does not get required treatment within certain period of time. This therefore means that the increase in the number of users goes directly with the increase in cases of such infections.
With increased cases of contact lens-induced infections, the manufactures, in collaboration with health organizations, have increased their hygiene and infection control measures, which have led to improved cleaning solutions and easier ways of performing contact lens care.
These are some infections that radiate from bacterial contamination due to poor cleaning and are in most cases sure to lead to serious eye complications, including corneal ulcers and blindness. By making hygiene practices more accessible as well as creating awareness about drug usage while getting treatment, manufacturers and health organizations working on reduction of the incidence of such infections.
One of the fact that is an expanding user base with associated, relatively low awareness about the proper care of lenses. With this rise in the number of contact lens users, the market size for treatments and preventive measures against contact lens-induced infections also increases.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Extended Wear and Overnight Contact Lenses Usage Influence the Contact-lens Induced Infections Market
Extended wear and overnight contact lenses, while allows more convenience and flexibility but also carry the greatest risk of infection with the lens remaining in contact with the eye for a longer period. This increases the chance of microbial growth and its subsequent ocular infection. Thus, effective antimicrobial treatments are required to manage such risks against eye health.
The growing popularity of extended wear and overnight lenses increases the demand for antimicrobial drugs aimed at the prevention and treatment of contact-lens-induced infections. The infection risks are greater with users, so pharmaceutical solutions targeting these concerns are increasingly in demand.
According to the eye health statistics published by American academy of ophthalmology around 1 million eye infections that require medical assistance from doctor each year.
Growth in the contact-lens-induced infection drugs market is observed for many reasons. On the factors front, increasing cases of extended wear lenses and rising e-commerce for prescription drugs, which are easily available. In addition, online pharmacies also enhance patients' access to medications required, thereby having accelerated demand in the market. Moreover, increasing awareness about eye care health and innovation in formulation developments develop the drugs market.
Development of Targeted Therapies Are Creating New Opportunities
The targeted ophthalmic therapies are specifically made in the manner to work with effect on the selective mechanisms of diseases with reduced side effects. Advanced drug delivery systems and molecular techniques are required for enhanced efficacy and better patient compliance. By addressing targeted locations, therapies with reduced side effects and improved patient compliance can be opened up to newer opportunities for the effective management of eye conditions.
In infections due to contact lenses, certain targeted therapies can vastly improve the outcomes. The drugs are designed for fighting specific pathogens that cause infections and reduce unnecessary exposure to broad-spectrum antibiotics which is also cutting down the side effects. It means greater precision in targeting the infection for better management and fewer side effects.
The targeted therapies in contact-lens-induced infection drugs market are open to much more opportunities with continuous developments. With refined treatments, the prevention and treatment of infections rise, and patient compliance increases. Also the creation of awareness about targeted therapies and the related benefits, along with pharmaceutical technology development, helps to keep up with demand create new opportunities in the market.
Rise in Adoption of Combination Therapies Is a Key Trend in Contact-lens Induced Infections Market
Combination therapies involve the administering of two drugs or more at the same time to target different phases of a condition. In this case, ophthalmology often combines the use of antibiotics with anti-inflammatory agents for the management of infections. This will not only affect pathogens that are causing an infection but also result in a decrease in inflammation, thereby improving the chances of improving the patients' conditions and hastening recovery.
Combining therapies against contact-lens-induced infections provides an all-inclusive treatment plan. Such therapies, with antibiotics combined with anti-inflammatory agents, fight both the infective process caused by microorganisms and the inflammatory response. These are complications very common in relation to the use of contact lenses. In this way, this dual approach increases the therapeutic effect and reduces recurrence.
On the rising complexity of infections, combination therapies are becoming quite important for the treatment of such infections. With rising cases of contact-lens related infection, there is a corresponding increase in the resort to multifaceted treatment options, hence the trend of adoption rate of combination therapies is shaping the market. Since the result-oriented nature of these combination therapies enhances patient satisfaction and adherence, they substantially fuel market growth.
Growing Concern of Antibiotic Resistance is One of the Key Barrier for the Market of Contact-lens Induced Infections
Antibiotic resistance is already proving to be a serious global concern, with healthcare givers taking more cautious modes of prescription. As bacteria develop resistance to normally applied antibiotics, there is a growing drive towards the use of these drugs in such a manner that will not lead to further development of resistance. This shift should help retain the effectiveness of existing antibiotics and lessen the spread of resistant strains.
In the context of contact lens-induced infections, the rise in antibiotic resistance has an effect on the pattern of prescription of those antibiotics. Owing to this fact, ophthalmologists are increasingly becoming sensitive to the patterns of resistance, and so they tend to opt for more directed therapy or other alternative options. This caution influences the dosing frequency and type of antibiotics prescribed in treating contact lens-related infections.
With rising resistance, traditional antibiotics become less effective. As a result, healthcare providers are less inclined to prescribe these drugs, leading to a decrease in their sales. This trend is particularly evident in contact-lens induced infections, where the efficacy of standard antibiotics is compromised by resistant strains.
With time, resistance is on the rise and traditional antibiotics are losing their edge. Thus the health administrators shy away from prescribing the drugs and the sales decline. The trend is most apparent in contact-lens induced infections where resistant strains compromise the effectiveness of the standard antibiotics.
Antibiotic resistance therefore threatens conventional treatments for contact-lens-induced infections because it reduces their efficacy, causing the market to be diverted to rarefied and more expensive specialized alternatives.
The contact-lens induced infections industry recorded a CAGR of 4.0% between 2019 and 2023. According to the industry, contact-lens induced infections generated USD 463.1million in 2023, up from USD 380.7 million in 2019.
Traditionally, the treatment for contact-lens induced infection has relied mostly on antibiotics against bacterial infection and anti-inflammatory agents in controlling related inflammation. The early approaches were majorly broad-spectrum antibiotics. Often it was found less effective due to rising bacterial resistance.
Later, the trend shifted to targeted therapy for better efficacy and fewer side effects. This period really showed with inventions like fluoroquinolones and other newer anti-inflammatory drugs, which greatly showed an increased understanding of ocular infections and resistance patterns.
Combination therapies, advanced drug delivery systems-these have the dual advantage of not only fighting infection and inflammation more effectively but also offering other advantages. Further developments in the future, with an enhanced focus on personalized medicine and therapy development against specific bacterial strains, hold great promise.
Future treatments are likely to be directed toward overcoming antibiotic resistance and improving patient compliance. The continual evolution in ocular therapeutics is required for improving and better-targeted solutions, commensurate with trends toward precision medicine and new forms of drugs.
Principal Consultant
Companies in the Tier 1 sector account for 51.6% of the global market, ranking them as the dominant players in the industry. Tier 1 players offer a wide range of products related to contact lens induced infection, have an established industry presence, offer continuous innovation, and have a significant influence in the field. Having financial resources enables them to enhance their research and development efforts and expand into new markets.
A strong brand recognition and a loyal customer base provide them with a competitive advantage. Prominent companies within Tier 1 include Alcon, Inc., Bausch + Lomb Inc., Allergan plc, Novartis International AG, and Pfizer Inc.
Tier 2 players dominate the industry with a 25.3% market share. Tier 2 firms have a strong focus on a specific technology and a substantial presence on the industry, but they have less influence than Tier 1 firms. The players are more competitive when it comes to pricing and target niche markets. New products and services will also be introduced into the industry by Tier 2 companies. Tier 2 companies include - Merck & Co., Inc., Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd. and Roche Holding AG.
Compared to Tiers 1 and 2, Tier 3 companies with smaller revenue spouts and less influence. Those in Tier 3 focus primarily on qualitative research and analysis while serving a smaller area. Prominent players Shionogi & Co., Ltd., Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd. and AstraZeneca plc
An analysis of the contact-lens induced infections industry is provided in various countries. Several regions throughout the world are examined, including Asia Pacific, North America, and Europe. India is forecast to remain the leader of Asia Pacific with a 7.1% CAGR through 2034. The United States is predicted to exhibit a 3.9% CAGR by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 3.9% |
| Canada | 3.2% |
| United Kingdom | 5.9% |
| Germany | 4.6% |
| India | 7.1% |
| Thailand | 5.8% |
| Malaysia | 5.1% |
According to American Academy of Ophthalmology, the information published in May 2023 stated that more than 70,000 cases occur only in the United States of America in each year. Keratitis is considered to be one of the growing eye health-related concerns. It happens to be an infection caused to the cornea due to the usage of contact lenses.
The growing cases of keratitis indicates a growing concern for contact lens-induced infection across the United States of America owing to the factors such as bad hygiene and extended wear, which massively contributes to the trend. Therefore, as awareness of the risks associated with these gains momentum, demand for medications used to treat and prevent such infections surges accordingly. The USA drug market against contact lens infection-based infection is growing owing to the enhanced requirement for highly effective treatments against vision-threatening conditions.
In Germany, the incidence of eye care products will follow suit, particularly for contact lenses, at a rate commensurate with increasing awareness of eye health and possible threats due to the use of the lenses. With this growing population of contact lens wearers, there will also be a corresponding increase in the cases of keratitis and other infections.
In the opinion of Deutsches Ärzteblatt International, an article to that effect, published in the official journals in 2022, over a million of about four million contact lens wearers in Germany complain of serious eye problems in the course of use. Yearly, 800-1,600 people develop microbial keratitis linked to wearing contact lenses.
The availability of eye care products, particularly contact lenses, in Germany is equal to the rate of increasing awareness regarding eye health and possibly the threats imposed when utilizing lenses. Of course, when more people are using contact lenses, there is a related increase in the cases of keratitis and other infections.
Hence, this growing number raises concern about contact lens-induced infections, and the market is increasing with that rate in Germany for the forecasted period with a CAGR of 4.6%.
The reason for the increased demand for contact lenses in urban areas is increased consumption of contact lenses within urban areas, both for vision and cosmetic correction. On the other hand, this increased use leads to an increased risk of conjunctivitis and keratitis infection, specifically with regard to inappropriate lens use or poor care. As concern for ocular health and potential complications from contact lens use increases, demand builds up for really effective treatment options.
The Indian market is huge and fast emerging for drugs used in treating contact-lens induced infections as awareness of these risks sets in amongst consumers and healthcare providers. Other factors contributing to this growth at the same time include an increased middle-class population, rise in disposable incomes, and easier access to healthcare. During 2024 to 2034, India is likely to grow at a CAGR of 7.1%.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
A description of the leading segments in the industry is provided in this section. The antibiotics, by drug type held 44.2% of the value share in 2023. Based on the distribution channel, hospitals held 39.8% of the market in 2023.
| Drug Type | Value Share (2024) |
|---|---|
| Antibiotics | 44.2% |
| Corticosteroids | 21.8% |
| Anti-inflammatory Drugs | 17.6% |
| NSAIDs | 16.4% |
Among drug type, antibiotics hold a major share in the market because they play a critical role in the treatment of bacterial infections like keratitis and conjunctivitis, which are reported as common complications of contact lens wear.
A high demand for newer, more effective antibiotics against the backdrop of rising antibiotic-resistant bacteria drives growth in this segment. For the prevention of complications, most prescribed by health personnel upon the onset of treatment in cases of eye infections are antibiotics. Awareness for contact lens users is increasing, and with fear of infectivity, the intake of antibiotics becomes dominant in the market.
| Route of Administration | Value Share (2024) |
|---|---|
| Oral | 29.5% |
| Topical | 25.8% |
| Ophthalmic Eye Drop | 34.7% |
| Injectable | 10.0% |
Ophthalmic eye drop type, a route of administration has greater market share in the global presbyopia therapeutic pipeline, as ophthalmic formulations provide rapid onset and high bioavailability that would assist in treating infections which are caused due to contact lens.
This provides precise administration, an advantage in that it ensures the proper dosing of antibiotics and anti-inflammatory medications and any other medication delivered applied locally at site of infection allowing them to be absorbed directly by infected tissue.
This route of administration is particularly critical in the case of keratitis and conjunctivitis, as prompt management for these conditions can prevent progression to serious complications. Upon their introduction, this approval and convenience offered by an eye drop formulation made these agents incredibly popular with professionals as well patients worldwide.
Certainly, with a greater comprehension and concern for ocular health-care leading to the search of proven but easy-to-use therapeutic solutions ophthalmic eye drops are increasingly prominent in particular within the lucrative area of contact lens-related conditions.
Customers can build long-term relationships with manufacturers by offering robust customer support, security offerings, troubleshooting, and improvements. Emerging industries with the potential to grow their ophthalmic infrastructure can present extensive opportunities. Incorporating a variety of products for ophthalmic care caused by inappropriate usage of contact lens can helps capture a larger market share.
The new drug development for ophthalmic solutions can be fostered through collaborations and partnerships with ophthalmic research institutions. Further new product launches are also anticipating the market over the forecasted period.
Recent Industry Developments in the Contact-lens Induced Infections Market
In terms of drug class, the industry is segregated into antibiotics, corticosteroids, Anti-inflammatory drugs and NSAIDs.
In terms of route of administration, the industry is segmented into oral, topical, ophthalmic eye drops and injectable.
In terms of sales channel, the industry is segmented into Hospitals, ophthalmology clinics, retail pharmacy chain, drug store and online sales
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, Middle East, and Africa have been covered in the report.
The market for contact-lens induced infections is expected to increase at a CAGR of 4.9% between 2024 and 2034.
The antibiotics segment is expected to occupy a 44.2% market share in 2024.
The market for contact-lens induced infections is expected to reach USD 792.6 million by 2034.
The United States is forecast to see a CAGR of 3.9% during the assessment period.
The key players in the contact-lens induced infections industry include Alcon, Inc., Bausch + Lomb Inc., Allergan plc, Novartis International AG and Pfizer Inc.
1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
5.1. By Drug Class
5.2. By Route of Administration
5.3. By Sales Channel
5.4. By Region
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
6.1. Antibiotics
6.2. Corticosteroids
6.3. Anti-inflammatory Drugs
6.4. NSAIDs
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
7.1. Oral
7.2. Topical
7.3. Ophthalmic Eye Drop
7.4. Injectable
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Sales Channel
8.1. Hospitals
8.2. Ophthalmology Clinics
8.3. Retail Pharmacy Chain
8.4. Drug Store
8.5. Online Sales
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
9.1. North America
9.2. Latin America
9.3. East Asia
9.4. South Asia & Pacific
9.5. Western Europe
9.6. Eastern Europe
9.7. MEA
10. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
11. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
12. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
13. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
17. Sales Forecast 2024 to 2034 by Molecule, Indication, and Sales Channel for 30 Countries
18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
19. Company Profile
19.1. Alcon, Inc.
19.2. Bausch + Lomb Inc.
19.3. Allergan plc
19.4. Novartis International AG
19.5. Pfizer Inc.
19.6. Merck & Co., Inc.
19.7. Santen Pharmaceutical Co., Ltd.
19.8. Teva Pharmaceutical Industries Ltd.
19.9. Roche Holding AG.
19.10. Shionogi & Co., Ltd.
19.11. Kowa Company, Ltd.
19.12. Otsuka Pharmaceutical Co., Ltd.
19.13. Sandoz International GmbH
19.14. Hikma Pharmaceuticals PLC
19.15. Dr. Reddy’s Laboratories Ltd.
19.16. AstraZeneca plc
19.17. Tarsus Pharmaceuticals, Inc.
Explore Healthcare Insights
View Reports
Contact-lens Induced Infections Market
